Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.
第一作者:
George,Somlo
第一单位:
City of Hope Comprehensive Cancer Center, Duarte, California. jweitzel@coh.org gsomlo@coh.org.
作者:
主题词
成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);BRCA1蛋白质(BRCA1 Protein);BRCA2蛋白质(BRCA2 Protein);苯咪唑类(Benzimidazoles);乳腺肿瘤(Breast Neoplasms);加利福尼亚(California);卡铂(Carboplatin);综合疗法(Combined Modality Therapy);无病生存(Disease-Free Survival);女(雌)性(Female);生殖细胞系突变(Germ-Line Mutation);人类(Humans);中年人(Middle Aged);肿瘤转移(Neoplasm Metastasis)
DOI
10.1158/1078-0432.CCR-16-2714
PMID
28356425
发布时间
2024-06-15
- 浏览31

Clinical cancer research
4066-4076页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文